NodThera

Thrilled to share that NodThera's management will be participating in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, held virtually on October 22-23. This is a valuable opportunity to dive into NodThera's latest advancements in NLRP3 inflammasome inhibition and our innovative approach to tackling chronic inflammation. We’re excited to connect with investors who share our vision for transforming how cardiometabolic and neurodegenerative diseases are treated and unlocking the potential of next-generation therapies. #Networking #NodThera #NLRP3 #inflammation #Innovation #Biotech

We had the pleasure of attending the Fierce Biotech Summit in Boston last week, where our CEO, Daniel Swisher, and CFO/CBO, Greg Chow, proudly accepted our #Fierce15 award! 🏆 Thank you to the Fierce team and everyone involved for hosting a great event, and congratulations to all the other #Fierce15 2024 winners! We are excited to be in such great company, shaping the future of biotech together. #NodThera #Award #Innovation #Biotech #NLRP3 #CardiovascularDisease #Obesity #Neuroinflammation

A recent article in The New York Times highlights a groundbreaking perspective on #inflammation as a key driver of various diseases, from heart disease to dementia. As the understanding of inflammation evolves, so does our approach to managing it. At NodThera, we are at the forefront of this transformation. Our work focuses on developing innovative therapeutics that precisely target #NLRP3 #inflammasome to tackle chronic conditions without compromising the body's essential defense mechanisms. We aim to bring a new class of anti-inflammatory drugs to market that can address the “silent” yet detrimental effects of chronic inflammation while preserving the balance necessary for overall health. The future of medicine is not about eliminating inflammation but managing it intelligently to enhance patient outcomes. We're excited to be part of this journey, leveraging our cutting-edge research to develop novel therapies that can potentially transform how we treat a myriad of conditions linked to chronic inflammation. Read the full NYT article here: https://lnkd.in/dN_irKBy

Spotted on the trading floor at the NYSE! Great to see NodThera on the screens at the New York Stock Exchange following our inclusion in Fierce Biotech's ‘Fierce 15’ 2024 special report. #NodThera #Fierce15 #Innovation #NYSE #Biotech #NLRP3

We are delighted to have been named by Fierce Biotech as one of its ‘Fierce 15’, in the 2024 special report highlighting the most innovative and promising #biotech companies in the industry. This recognition follows the significant progress we have made towards realizing the full potential of targeting the #NLRP3 #inflammasome and our bright future as we progress the clinical development programs in #CardiovascularDisease, #Obesity and #Neuroinflammation. Learn more about why we stand out here: https://lnkd.in/eXVdVv4z #NodThera #Fierce15 #Innovation 

Please join us in extending a warm welcome to Greg Chow, NodThera’s new Chief Financial and Business Officer! Greg brings over 25 years of public and private company leadership experience, including deep expertise in capital markets, #DrugDevelopment and business development. Over the course of his career, he helped lead the execution of major financing rounds, including a $254 million Series F fundraise at Freenome Holdings, where he most recently served as CFO. Find out more about Greg’s #appointment and experience here: https://lnkd.in/e6RMyFfH #NewHire #NeuroInflammation #WelcomeToTheTeam #NLRP3

We are pleased to share NodThera’s latest research publication detailing the preclinical pharmacology of our clinical-stage drug candidate, NT-0796, which has successfully completed two Ph1b/2a clinical studies in Parkinson’s disease and obese patients at cardiovascular risk. 🔬 Key Highlights: Mechanism of Action: NT-0796 is metabolized by carboxylesterase-1 (CES1) to produce NDT-19795, which inhibits the NLRP3 inflammasome. Potency: In human monocytes/macrophages, NT-0796 demonstrates superior potency compared to NDT-19795 alone. Cellular Dynamics: NT-0796 accumulates rapidly within cells, reaching higher concentrations than those in the medium, followed by conversion to NDT-19795 in CES1-expressing cells. Pharmacodynamics: NT-0796 acts as an effective vehicle to deliver NDT-19795, providing a robust NLRP3 inhibition by leveraging the dynamics of CES1 metabolism. This study underscores our commitment to developing pioneering treatments targeting #NLRP3 #inflammasome-related diseases. Dive into the full study to learn more: https://lnkd.in/eaYk2f5f

In a recent discussion with Jill Drachenberg from BioSpace, Alan Watt, our President & Chief Scientific Officer, highlights NodThera’s innovative approach to addressing chronic neuroinflammation, marking a potential game-changer in Parkinson’s treatment. Our #NLRP3 #inflammasome inhibitors show promise not only in halting brain inflammation in Parkinson’s disease but also in addressing a range of chronic inflammatory conditions, including #obesity and #cardiovascularDisease. Read more here: https://lnkd.in/es_g27ay #NodThera #Neuroinflammation #DrugDiscovery #Biotech

We are excited to share that tomorrow, our Chief Scientific Officer, Alan Watt, will speak at the Future of Healthcare Investment Forum 2024 organized by LSEG (London Stock Exchange Group). He will join an expert panel on Metabolic Diseases to share insights from our pioneering research. Don't miss this opportunity to learn how we are shaping the future of healthcare. Follow this link to register:   https://lnkd.in/dGbknNHf #HealthcareInnovation #MetabolicDiseases #NodThera #FutureOfHealthcare #InvestmentForum2024 #Biotech

Today we reached another exciting clinical milestone in our journey to deliver a paradigm shift in the treatment of chronic inflammatory diseases, announcing positive data from a Phase Ib/IIa #cardiovascular risk study of our lead brain-penetrant #NLRP3 #inflammasone inhibitor candidate, NT-0796. The trial met its primary endpoint, demonstrating a highly statistically significant and rapid reduction of C-reactive protein (CRP), a key biomarker of chronic #cardiometabolic inflammatory diseases, in inflamed obese subjects dosed with NT-0796 compared to placebo. The study also saw reductions in body weight, the most pronounced among high-risk subgroups, supporting the anti-obesity potential of the molecule. Preparations are now underway for a Phase II #obesity study alongside other Phase IIa studies in additional cardiometabolic diseases and #ParkinsonsDisease. Learn more: https://bit.ly/4aYdBPR #NeuroInflammation #DrugDiscovery #Biotech